Log In
BCIQ
Print this Print this
 

AV-203, CAN-017

  Manage Alerts
Collapse Summary General Information
Company Aveo Pharmaceuticals Inc.
DescriptionErb-b2 receptor tyrosine kinase 3 (ERBB3; HER3; EGFR3)-targeted antibody
Molecular Target Erb-b2 receptor tyrosine kinase 3 (ERBB3) (HER3) (EGFR3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerBoehringer Ingelheim GmbH;
Canbridge Life Sciences Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$134.0M

$1.0M

$133.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today